India Contract Development and Manufacturing (CDMO) Market to Reach $31.23 Billion by 2033 | Leading companies - Aurobindo Pharma Limited, Dr. Reddy's Laboratories Ltd., Sun Pharmaceutical Industries Ltd.

Leander, Texas and Tokyo, Japan - Dec.10.2025
As per DataM intelligence research report" The India contract development and manufacturing (CDMO) market size reached US$ 16.27 Billion in 2024 and is expected to reach US$ 31.23 Billion by 2033, growing at a CAGR of 7.6% during the forecast period 2025-2033." Global pharma outsourcing and India's cost-effective capabilities are driving CDMO market expansion.

Download your exclusive sample report today: (corporate email gets priority access):
https://www.datamintelligence.com/download-sample/india-contract-development-and-manufacturing-cdmo-market?Prasad

India: Recent Industry Developments

✅ In November 2025, Syngene International opened a new biologics manufacturing facility in Bangalore The facility is designed to meet USFDA standards for monoclonal antibody production It positions India as a high-quality hub for complex biologic outsourcing

✅ In October 2025, Cipla strengthened its CDMO arm with a strategic investment in mRNA technology The investment aims to capture the growing demand for vaccine and gene therapy manufacturing It moves the Indian industry up the value chain beyond small molecules

✅ In September 2025, Piramal Pharma Solutions announced a capacity expansion for high-potent APIs The expansion targets the oncology market where specialized handling is required It supports the global supply chain for cancer medications

✅ In August 2025, Dr. Reddy's Laboratories launched a dedicated "Digital CDMO" platform for clients The platform provides real-time visibility into project timelines and quality data It improves transparency and trust for Western pharma partners

United States: Recent Industry Developments

✅ In December 2025, The U.S. Congress passed the "BIOSECURE Act" restricting federal contracts with certain foreign biotech firms The legislation has prompted U.S. pharma companies to shift contracts from China to India It creates a massive tailwind for Indian CDMOs as "China Plus One" beneficiaries

✅ In November 2025, Pfizer announced a strategic partnership with an Indian CDMO for legacy drug production The deal allows Pfizer to free up internal capacity for new innovative therapies It validates the quality and reliability of Indian manufacturing

✅ In October 2025, A U.S. private equity firm acquired a controlling stake in a mid-sized Indian CDMO The investment aims to scale the company's operations for the U.S. generics market It reflects strong investor confidence in the growth of the Indian CDMO sector

✅ In September 2025, The FDA opened a new office in Hyderabad to increase inspection frequency The presence aims to streamline the approval process for Indian facilities exporting to the U.S. It ensures that Indian CDMOs maintain compliance with U.S. safety standards

India Contract Development and Manufacturing (CDMO) Market: Drivers
The India CDMO market is expanding as pharmaceutical and biotech companies increasingly outsource development, manufacturing, and clinical trial support to specialized contract organizations. CDMOs offer formulation development, API production, clinical supply, and commercial-scale manufacturing, helping clients reduce costs, accelerate timelines, and navigate regulatory complexities. India's skilled workforce, cost efficiency, and regulatory compliance make it an attractive destination for global pharmaceutical outsourcing. Advanced facilities and quality standards enable production of complex biologics, sterile injectables, and solid oral dosage forms.

Growth is supported by rising R&D investment, biotechnology pipeline expansion, and international collaborations. CDMOs are investing in continuous manufacturing, process optimization, and quality management systems to meet evolving client needs. Expansion in specialty therapeutics, personalized medicine, and biosimilars further strengthens the market. With increasing reliance on outsourcing for efficiency and compliance, India's CDMO sector is poised for continued expansion.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/india-contract-development-and-manufacturing-cdmo-market?Prasad

India Contract Development and Manufacturing (CDMO) Market: Major Players
Aurobindo Pharma Limited, Dr. Reddy's Laboratories Ltd., Sun Pharmaceutical Industries Ltd., Lupin Limited, Cipla, NATCO Pharma Limited, Hetero Labs Limited, Cadila Pharmaceuticals, Biocon, Intas Pharmaceuticals Ltd., and others.

Segment Covered in the India Contract Development and Manufacturing (CDMO) Market:
By Service Type
The market is segmented into drug development services 40%, manufacturing services 45%, and analytical & regulatory support 15%, with manufacturing services dominating due to increasing outsourcing by pharmaceutical companies. Drug development services are growing with rising R&D demand, while analytical and regulatory support aids compliance. Expanding biopharmaceutical pipelines drive adoption across services. Advanced capabilities and cost-efficiency strengthen market growth.

By Scale of Operation
Scale of operations includes small-scale 25%, mid-scale 35%, and large-scale 40%, with large-scale dominating due to high-volume production requirements of pharmaceutical and biologic drugs. Mid-scale CDMOs are growing with specialized contract projects. Small-scale operations serve niche and early-stage development needs. Increasing domestic and international demand supports scaling and market expansion.

By End-User
End-users include pharmaceutical companies 50%, biotechnology firms 30%, and others 20%, with pharmaceutical companies dominating due to outsourcing of drug development and manufacturing processes. Biotechnology firms are growing with biologics and specialty molecules. Other end-users include nutraceutical and cosmetic industries. Rising R&D outsourcing and demand for cost-effective production drive end-user adoption.

Purchase this report before year-end and unlock an exclusive 30% discount:
https://www.datamintelligence.com/buy-now-page?report=india-contract-development-and-manufacturing-cdmo-market
(Purchase 2 or more Repots and get 50% Discount)

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?Prasad

✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.